HARMONY BIOSC.HLD.-,00001 Logo
US4131971040
A2QBSF
HRMY

HARMONY BIOSC.HLD.-,00001

Prognoza

Średnia cena docelowa analityków wynosi 45,17 € (+50,02%). Mediana wynosi 44,65 € (+48,29%).

Kupuj
  8
Trzymaj
  3
Sprzedaj
  2

Dyskusje w społeczności

Nie ma jeszcze dyskusji o tym aktywie.

Rozpocznij dyskusję

  • Harmony Biosciences outlines second growth chapter with BP-205 and acquisition plans

    Harmony is building on revenue driver WAKIX (on track for over $1 billion) and a broader pipeline approach. The company has about $963 million in cash, positions BP-205 as a leading orexin‑2 agonist and plans two to three business-development transactions expected to generate revenue in 2028–2032. In parallel, Harmony is defending WAKIX’s patent portfolio against generics and anticipates loss of exclusivity in March 2030. Several clinical milestones for BP-205 are targeted for late 2024 to mid-2026. » Więcej na de.investing.com


  • Harmony Biosciences reaches 52-week high after strong Wakix numbers

    Harmony Biosciences shares rose to a new 52-week high of $42.70 and have a market capitalization of about $2.49 billion. In the second quarter, adjusted earnings per share of $1.28 beat expectations, and Wakix revenue hit a record $261.3 million, confirming the full-year guidance of $1.00–1.04 billion. Analysts remain positive (including outperform ratings with price targets of $60–70), despite ongoing IP disputes and competition from orexin agonists. InvestingPro sees the stock at a fair value of $59.06 and rates the financial condition as "EXCELLENT". » Więcej na de.investing.com


  • Harmony Biosciences presents strategy following WAKIX and expands CNS pipeline

    Harmony outlines three strategic pillars: expanding the pitolisant franchise with Pitolisant GR (PDUFA April 27) and Pitolisant HD; advancing BP-205 as a potential best-in-class orexin-2 agonist; and developing EPX-100 for rare epilepsies. WAKIX delivered record quarterly sales and funds the pipeline growth, while key milestones are mostly expected in 2027/2028. BP-205 showed strong efficacy, rapid absorption and no relevant safety signals in early studies; EPX-100 demonstrated substantial seizure reductions in Dravet syndrome. The stock closed at $38.50 (-3.19%). » Więcej na de.investing.com


  • Harmony Biosciences posts strong Q1 results, keeps full-year revenue guidance above $1 billion

    Harmony Biosciences reported Q1 2026 revenue of $215.4 million, a 17% year-over-year increase driven by continued adoption of WAKIX (pitolisant). Management reaffirmed full-year 2026 net revenue guidance of over $1 billion and highlighted strong operating leverage and cash generation funding its late-stage pipeline. The company is pursuing pediatric narcolepsy approval and exploring indications including idiopathic hypersomnia and Prader-Willi syndrome, supporting investor optimism about lifecycle and pipeline growth. » Więcej na finance.yahoo.com


  • Harmony Biosciences: WAKIX grows, heavy investments weigh on quarterly profit

    Harmony reported Q1 2026 results: WAKIX revenue rose 17% to $215.4 million but missed consensus, and diluted earnings per share fell to $0.55, well below expectations. Management reaffirmed the full-year revenue guidance of $1.0–1.04 billion, attributing the earnings miss to high strategic investments, license costs and increased R&D spending. The company holds about $870.5 million in cash and highlights growth drivers such as enteric-coated and high‑dose pitolisant programs, a broad pipeline and legal actions to defend patents. Despite near-term profitability pressure, Harmony sees a clear path for WAKIX to reach the billion-dollar mark and plans to step up business development transactions. » Więcej na de.investing.com

Dane finansowe

W ostatnim kwartale HARMONY BIOSC.HLD.-,00001 osiągnęła przychody w wysokości 237,41 mln € i zysk netto w wysokości 42,55 mln €

(EUR) wrzesień 2026
YoY
Przychody 237,41 mln 16,35%
Zysk brutto 166,18 mln 8,46%
Zysk netto 42,55 mln 1,83%
EBITDA 60,28 mln 3,70%

Dane fundamentalne

Wskaźnik Wartość
Kapitalizacja rynkowa
1,77 mld €
Liczba akcji
58,72 mln
Maksimum/minimum z 52 tygodni
39,63 € - 23,60 €
Dywidendy Nie
Beta
0,98
C/Z (PE Ratio)
10,75
PEG (PEG Ratio)
-2,18
C/WK (PB Ratio)
1,80
C/S (PS Ratio)
1,97

Profil spółki

Harmony Biosciences Holdings, Inc., firma farmaceutyczna będąca na etapie komercjalizacji, opracowuje i wprowadza na rynek terapie dla pacjentów z rzadkimi zaburzeniami neurologicznymi w Stanach Zjednoczonych. Jej produkt WAKIX to lek stosowany w leczeniu nadmiernej senności w ciągu dnia u dorosłych pacjentów z narkolepsją. Spółka wcześniej funkcjonowała jako Harmony Biosciences II, Inc. i zmieniła nazwę na Harmony Biosciences Holdings, Inc. w lutym 2020 roku. Harmony Biosciences Holdings, Inc. została założona w 2017 roku i ma siedzibę w Plymouth Meeting w stanie Pensylwania.

Nazwa
HARMONY BIOSC.HLD.-,00001
CEO
Jeffrey Dayno
Siedziba Plymouth Meeting, pa
Stany Zjednoczone
Strona internetowa
Sektor
Materiały podstawowe
Branża
Chemikalia
Debiut giełdowy
19.08.2020
Pracownicy 293

Symbole giełdowe

Giełda Symbol
NASDAQ
HRMY
🍪

Parqet  używa plików cookie. Dowiedz się więcej